FULC Logo

Fulcrum Therapeutics, Inc. (FULC) 

NASDAQ
Market Cap
$210.91M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
142 of 776
Rank in Industry
89 of 433

Largest Insider Buys in Sector

FULC Stock Price History Chart

FULC Stock Performance

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug …

Insider Activity of Fulcrum Therapeutics, Inc.

Over the last 12 months, insiders at Fulcrum Therapeutics, Inc. have bought $492,028 and sold $59,050 worth of Fulcrum Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Fulcrum Therapeutics, Inc. have bought $13.54M and sold $1.5M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Sapir Alex (See Remarks) — $492,028.

The last purchase of 43,360 shares for transaction amount of $492,028 was made by Sapir Alex (See Remarks) on 2024‑03‑04.

List of Insider Buy and Sell Transactions, Fulcrum Therapeutics, Inc.

2024-05-07SalePrincipal Accounting Officer
236
0.0004%
$7.76$1,831+1.86%
2024-03-08SaleVice President, Finance
4,884
0.0084%
$11.72$57,219-30.14%
2024-03-04PurchaseSee Remarks
43,360
0.0707%
$11.35$492,028-31.48%
2023-05-10SalePrincipal Accounting Officer
210
0.0004%
$3.31$695+46.79%
2023-01-20Purchasedirector
1.92M
3.8009%
$13.00$25M-68.65%
2023-01-13SaleInterim President & CEO
6,766
0.0142%
$15.00$101,490-71.09%
2023-01-04Purchasedirector
180,703
0.3049%
$7.28$1.31M-52.11%
2022-12-27Purchasedirector
4,089
0.009%
$5.99$24,510-34.35%
2022-12-19Purchasedirector
98,787
0.2145%
$5.90$582,814-34.35%
2022-12-16Purchasedirector
1.34M
3.0203%
$5.42$7.27M-25.98%
2022-12-15Purchasedirector
237,029
0.5283%
$5.50$1.3M-27.65%
2022-12-14Purchasedirector
824,600
1.8392%
$5.46$4.5M-27.11%
2022-06-07Sale
71,435
0.1753%
$8.09$577,895-23.70%
2022-06-02Sale
16,689
0.043%
$7.92$132,162-16.89%
2022-04-07Sale
5,631
0.0145%
$24.02$135,228-68.29%
2022-04-01Sale
52,552
0.1313%
$24.26$1.27M-69.08%
2021-08-11SaleSee Remarks
28,000
0.0899%
$23.75$665,000-25.57%
2021-08-10SaleSee Remarks
32,000
0.0815%
$17.50$560,000-19.71%
2021-08-10SaleChief Scientific Officer
51,785
0.1326%
$17.60$911,416-19.71%
2021-06-28Purchasedirector
10,000
0.0312%
$9.16$91,600+68.04%

Insider Historical Profitability

0.86%
Sapir AlexSee Remarks
43360
0.0695%
$3.3810
RA CAPITAL MANAGEMENT, L.P.director
11609704
18.6051%
$3.3870<0.0001%
LEVIN MARK J
5962202
9.5547%
$3.3810+2.11%
Third Rock Ventures III, L.P.10 percent owner
5962202
9.5547%
$3.3810+2.11%
Third Rock Ventures IV, L.P.10 percent owner
2343154
3.755%
$3.3810+2.11%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$109.6M18.6811.61M0%+$00.11
RTW Investments, LP$55.19M9.415.85M+6.87%+$3.55M0.83
Fidelity Investments$50.64M8.635.36M-5.63%-$3.02M<0.01
Cowen Group$35.06M5.983.71M+6.91%+$2.27M1.12
Suvretta Capital Management, LLC$26.89M4.582.85M-48.39%-$25.21M1.14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.